Cornea and external disease

Tebentafusp (IMCgp100; Immunocore) demonstrated a statistically significant and clinically meaningful improvement in overall survival (OS) as a first-line treatment in patients with metastatic uveal melanoma, according to Phase 3 clinical trial results presented at the American Association for Cancer Research (AACR) Annual Meeting 2021.

In the study, 378 patients were treated with tebentafusp (n = 252) or investigator’s choice of therapy (n = 126).

In the tebentafusp group versus the investigator’s choice group, there was an estimated 1-year OS rate of 73.2% and 58.5%,…


View Conference Coverage

Take a look at some of our conference coverage, visit our roundup section.

Conference Roundup

  1. Apr 13, 2021

Investigational therapy improves overall survival in metastatic uveal melanoma

Tebentafusp (IMCgp100; Immunocore) demonstrated a statistically significant and clinically meaningful improvement in overall survival (OS) as a first-line treatment in patients with metastatic uveal melanoma, according to Phase 3 clinical trial results presented at the American Association for…

Journal Scan

  1. Mar 18, 2021

Should CXL be performed on early-stage patients with keratoconus?

The vision‐related quality of life of patients with early keratoconus remains high but sharply declines after disease progression and does not improve after corneal cross‐linking, according to a study.

In this combined prospective/cross‐sectional…